Advanced Search


Study ID Status Title Patient Level Data
ROP105323 Completed A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release Tablets (REQUIP IR) or Ropinirole Prolonged Release Tablets (SK&F-101468) in Advanced Stage Parkinson’s Disease Subjects who are not Adequately Controlled on L-dopa.
ROP106064 Completed Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease - an Open-Label, Uncontrolled Study -
ROP109087 Completed An open label, repeat dose, dose escalation study conducted in Parkinson's Disease patients to characterize the pharmacokinetics and effect of food on ropinirole prolonged release (PR/CR) 12mg tablets. Study Listed on
ROR104836 Completed A parallel group study to evaluate the efficacy and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation and rebound for a further 40 weeks open-label extension treatment period in subjects suffering from moderate to severe Restless Legs Syndrome. Study Listed on
ROR106470 Completed An open label, repeat dose, dose escalation study conducted in RLS patients to characterize pharmacokinetics and food effect of ropinirole controlled release for RLS
ROTA-Meta-Analysis-201212 Completed Integrated safety summary of GSK Biologicals’ HRV vaccine (Rotarix™)
ROX104805 Completed A 4-Week, Randomized, Double-Blind, Cohort Study to Evaluate the Safety and Tolerability of Converting from Ropinirole Immediate Release (IR) to Ropinirole Controlled Release for RLS (CR-RLS) Formulation (Formerly Ropinirole Extended Release [XR]) in Patients with Restless Legs Syndrome (RLS) Study Listed on
RRL103628 Completed An Open-Label, Parallel-Group, Repeat-Dose Study to Investigate the Effects of End Stage Renal Disease and Haemodialysis on the Pharmacokinetics of Ropinirole (Study RRL103628) Study Listed on
RRL103660 Completed A 12-Week, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Flexible Dose Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome (RLS) in RLS Patients with Sleep Disturbance and Periodic Limb Movements (PLM) During Sleep Study Listed on
RRL106721 Completed A multicenter 3:1-randomized placebo-controlled double-blind Phase IIIb study on the effects of Ropinirole on mood/(subclinical) depression in the therapy of patients with moderate to severe idiopathic RLS in Germany
RXP110908 Completed Study RXP110908, a polysomnography study of GSK1838262 (XP13512) extended release tablets versus placebo in the treatment of Restless Legs Syndrome (RLS) and associated sleep disturbance
S194-401 Completed A multi-center, randomized, evaluator-blind, parallel-group evaluation of the efficacy, safety, and tolerability of Duac Akne Gel and Epiduo Gel in the topical treatment of facial acne vulgaris
S2110367 Completed A Randomized, Open Label Study to Evaluate the Oral Tolerability of a Nicotine Prototype
S2111378 Completed A Pilot Study to Evaluate Relief of Provoked Acute Craving by Nicotine Mouth Strip, Nicorette ® Nicotine Lozenge and Gum Study Listed on
S2W106188 Completed A multicenter study to determine the clinical characteristics of the temporal aspects of migraine in a Canadian population: Clinical Study Of Migraine Evolution (C-SOME)
S3010567 Completed A Single Dose Bioequivalence Study of 2mg and 4mg Nicotine Lozenges
S3250493 Completed Simultaneous fMRI/EEG of the 4 mg Nicotine Lozenge in Relief of Cognitive Impairment Associated with Nicotine Withdrawal
S3820642 Completed A Pharmacokinetic Evaluation of Nicotine Patches in Smokers
S3B20032 Completed A four-week, open, multicenter study to assess the safety and efficacy of 1 mg once daily (QD) of GR68755 in female subjects with severe diarrhea-predominant irritable bowel syndrome (IBS) who have frequent bowel urgency
S3B30040 Completed A Twelve-Week, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 0.5 mg QD, 1 mg QD and 1 mg BID of Alosetron in Female Subjects with Severe Diarrhea-predominant IBS Who Have Failed Conventional Therapy
S3B30048 Completed A 12-Week, Randomized, Double-Blind, Placebo- Controlled Study of PRN BID and Fixed Dosing Regimens of Alosetron in Female Subjects with Severe Diarrhea-Predominant Irritable Bowel Syndrome Who Have Failed Conventional Therapy
S3B40042 Completed A randomize, placebo-controlled, crossover study to measure the effect of alosetron on mucosal blood flow in female healthy volunteers and diarrhea-predominant IBS subjects
S6491365 Completed A Single Dose Bioequivalence Study of 2 different doses of Mini Cherry Nicotine Lozenges
S7120994 Completed Evaluation of the nicotine lozenge in relief of provoked acute craving
S7121359 Completed Evaluation of the Nicotine Mini Lozenge in Relief of Provoked Acute Craving



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.